Although elevated levels of ceramide in the CSF of patients with Alzheimer’s disease [33] could also be attributed to an inhibition of ceramide-metabolizing enzymes, significantly increased levels of total ceramide and of individual ceramide species in brains of patients with AD corresponded to an upregulated transcription of ASM [34]. The gene discussed is SMPD1; the disease is early-onset autosomal dominant Alzheimer disease.